Skip to Main Content

Author Details

Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
2004
85
31
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36862966Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.JCO Precis Oncol2023
37944073Clonal Hematopoiesis in Patients With Cancer: How Much Should We Care?JCO Precis Oncol2023
37601428An atypical promyelocytic sarcoma and pleural effusion in a patient with Gorham's disease: Efficiency of ATRA/ATO-based treatment.Clin Case Rep2023
37391357Therapy-related myelodysplastic syndromes in the genomics era.Bull Cancer2023
37085611UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.Leukemia2023
36916192Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.Clin Cancer Res2023
34172895Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.Leukemia2022
35741030Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.Cells2022
35443031Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.Blood2022
35816234Acute Abdominal Complications in Deeply Neutropenic Onco-Hematology Patients: A Retrospective Series of 105 Cases.World J Surg2022
35747848Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.Hemasphere2022
36201165Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.Clin Cancer Res2022
33043739Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.Leuk Lymphoma2021
33881523Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.Blood2021
33570629Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.Blood Adv2021
33554699<i>ATG2B/GSKIP</i> in <i>de novo</i> acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.Leuk Lymphoma2021
34410352Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.Blood2021
34492730Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.J Cell Mol Med2021
34423258Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers.Hemasphere2021
34625784Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.Blood Adv2021
34153714Impact of COVID-19 on healthcare organisation and cancer outcomes.Eur J Cancer2021
34172893Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.Leukemia2021
32350520Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.Blood2020
35121871Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.Nat Cancer2020
31814054Spontaneous molecular response of IDH2 acute myeloid leukemia.Ann Hematol2020
32917576Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.Clin Lymphoma Myeloma Leuk2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32893715Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.Gut Microbes2020
31573071Bone marrow metastases mimicking acute leukaemia.Br J Haematol2019
31723833Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML.Hemasphere2019
31440708Myelodysplastic Syndrome in Hemodialysis Patients.Kidney Int Rep2019
31413091Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state.Haematologica2019
31578525Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.Nature2019
31430225Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.J Clin Oncol2019
29115897Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.Leuk Lymphoma2018
29692343Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.Blood2018
29457515ANTIBIOSTOP, for all?Infect Dis (Lond)2018
29479068Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.Leukemia2018
27909895Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient.Infection2017
28131982Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.Leuk Res2017
28498370Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.Blood Cancer J2017
28516957ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Nat Commun2017
25856206Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).Leuk Lymphoma2016
26566875Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Cancer Discov2016
26316320Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.Leukemia2016
27270779Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Nat Med2016
27270773Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".Nat Med2016
27527698The Role of Additional Sex Combs-Like Proteins in Cancer.Cold Spring Harb Perspect Med2016
27135740Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Nat Med2016
26980726Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Blood2016
  • 1 - 50 of 85

Recommended Authors

Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 2
Jennifer N Saultz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 1
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 2
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 3
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 1
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 8
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 4
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 14
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 8
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 10
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 10
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 9
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 3
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 7
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 4
Gudrun G??hring
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 6
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 13
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 7
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 2
Luca Malcovati
University of Pavia & S. Matteo Hospital
Career Start Year 1997
Number of shared co-authors 16
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 9
Lucy A Godley
The University of Chicago
Career Start Year 1994
Number of shared co-authors 15
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 17
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 19
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 11
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 6
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 21
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 11
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 26

Collaborators

Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 21
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 19
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 11
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 10
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 8
Claude Gardin
Avicenne Hospital
Co-authored papers 7
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Co-authored papers 6
Emmanuelle Clappier
Saint-Louis Hospital
Co-authored papers 5
Il??ana Antony-Debr??
INSERM, France Villejuif Universite Paris-Saclay
Co-authored papers 4
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 4
Robert K Bradley
Fred Hutchinson Cancer Research Center, University of Washington
Co-authored papers 4
Scott A Armstrong
Boston Children's Hospital
Co-authored papers 4
Camille Lobry
INSERM U1170, Universite Paris Saclay
Co-authored papers 4
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Heidi Dvinge
University of Wisconsin School of Medicine and Public Health
Co-authored papers 3
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 3
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Co-authored papers 2
Jean Soulier
University of Paris
Co-authored papers 2
Ari Melnick
Co-authored papers 2
Rémi Favier
Co-authored papers 2
Elisa de Stanchina
Co-authored papers 2
Paul M Thomas
Northwestern University
Co-authored papers 2
Neil L Kelleher
Northwestern University
Co-authored papers 2
Odile Bera
Co-authored papers 2
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 2
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 1
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Justine Pasanisi
INSERM UMR , St Louis Hospital, University of Paris
Co-authored papers 1
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 1
Kevin H Lin
Duke University
Co-authored papers 1
Release 1.2